羅氏診斷購買AvanSciBio公司組織分離ZL技術

　　美國時間2014年12月10日，羅氏診斷宣布與AvanSci Bio公司簽署了一項收購協議，購買與高性能顯微組織滑動式切片分離的相關產品，包括儀器、軟件及研究人員使用的耗材，以及臨床提取、具有較高精確度和純度用于后續分子分析的特定區域，包括實時PCR、微陣列和測序。

　　AvanSci Bio正在申請包括自動MilliSect儀器的ZL技術。相比手動清掃方法和激光顯微切割系統，這種獨特的技術非常精確且易于使用、非常實惠。MilliSect系統的高特異性能夠使一個腫瘤富集大于90%的樣本用于分子分析。

　　“這種創新系統將擴大我們的診斷工具套件，讓我們能聯合診斷H&E染色通過高質量的樣品制備測序分析。”羅氏組織診斷和測序解決方案負責人Dan Zabrowski說道：“這也將使我們能迎接腫瘤異質性的關鍵挑戰。”

Roche Diagnostics purchases tissue dissection technology from AvanSci Bio

　　2014 /PRNewswire/  --Roche Diagnostics (SIX: RO, ROG； OTCQX: RHHBY) has signed a definitive Asset Purchase Agreement with AvanSci Bio for all products associated with the high performance microdissection of slide mounted tissue sections. The system consists of instrumentation, software and consumables used by researchers and clinicians to extract specific areas of tissue with high precision and purity for subsequent molecular analysis including real time PCR, microarrays and sequencing.

　　AvanSci Bio's patent-pending technology includes the automated MilliSect?* instrument. This unique technology is highly precise, easy to use, and very affordable when compared to manual dissection methods and laser microdissection systems. The MilliSect? system's high specificity and quality enables a greater than 90% tumor enriched sample for molecular analysis. The system will be tested at select customer sites in 2015 as part of a broader development program for a future generation instrument.

　　"This innovative system will expand our diagnostic tool kit allowing us to link the diagnostic hematoxylin and eosin (H&E) stain with sequencing analysis through high quality sample preparation," said Dan Zabrowski, Head of Roche Tissue Diagnostics and Sequencing Solutions. "It will also enable us to meet the critical challenge of tumor heterogeneity."

　　Tumor tissue staining gives researchers and clinicians important information about both tissue context and spatial relationships and tumor heterogeneity (which stems from the evolution of multiple subclones within the tumor). Information obtained from stained areas enable researchers and clinicians to pinpoint and extract more precise regions of interest within the tissue, resulting in purer samples of sufficient quantity that can then be used for sequencing. In addition, the analytical sensitivity of sequencing improves with higher sample purity as does subsequent data analysis and interpretation.

　　"We are very pleased that Roche has decided to pursue this Asset Purchase Agreement with AvanSci Bio," said Rob Perry, CEO, AvanSci Bio. "We see Roche as the leader in tissue based diagnostics, molecular diagnostics and oncology, as well as tumor sample enrichment technology, which puts them in a unique position to maximize the impact our technology will have on the rapidly evolving field of sequencing and in improving patient care."

　　Roche continues to invest in the bridge between the anatomical pathology and genomics labs as researchers and clinicians increasingly rely on pure, tumor-enriched slide mounted tissue samples for sensitive and efficient molecular analysis. As the challenge of tumor heterogeneity is addressed through slide-based tissue diagnostic technologies and the analytical sensitivity of next generation sequencing improves, patients may benefit through more accurate and effective targeted therapies.

　　*The MilliSect? instrument targets a 100mm2 to 100 μm2 level of resolution (what AvanSci refers to as " meso" dissection range).